462 filings
Page 11 of 24
6-K
3esd1zls
27 Nov 20
Notification of Dilution of Voting Rights
6:10am
6-K
5k5f3c
17 Nov 20
Chi-Med Announces US$100 Million Equity Investment by CPP Investments
6:17am
6-K
te1xxeakx0w6
5 Nov 20
Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting
6:07am
6-K
vcodnrh qwblxf80
30 Oct 20
Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences
9:04am
6-K
nw4 23f758
30 Oct 20
Current report (foreign)
6:29am
6-K
u977wjcq8k6vohkc 1x
30 Sep 20
Current report (foreign)
6:12am
6-K
4n7y8 z7v412ef
21 Sep 20
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
6:16am
6-K
acxeowkx um
17 Sep 20
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
7:00am
6-K
qrk xcki0xrz3gy5l
4 Sep 20
Current report (foreign)
6:27am
6-K
nylxu37sa2dvhnzhj
3 Sep 20
Current report (foreign)
7:29am
6-K
vc5012z7
28 Aug 20
Current report (foreign)
6:39am
6-K
gxre2lnm
24 Aug 20
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
6:53am
6-K
71gx00 3mkum3d0
12 Aug 20
Current report (foreign)
6:33am
6-K
4i1a3z
10 Aug 20
Current report (foreign)
6:15am
6-K
ba0kq
30 Jul 20
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
10:29am
6-K
04j nix9757
30 Jul 20
Current report (foreign)
6:16am
S-8
s30924kom863ah8
30 Jul 20
Registration of securities for employees
6:10am
6-K
e4jrobpobpw8wup3m4am
28 Jul 20
Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
6:28am
6-K
vffddilkb6d
24 Jul 20
Current report (foreign)
6:30am
6-K
bu25g1o91o
8 Jul 20
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
6:11am